Unit 2, 10 Rodborough Road
New South Wales
Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that improve the clinical management of chronic respiratory and autoimmune diseases.
Pharmaxis has a diversified portfolio of products at various stages of development which target attractive international markets across a range of diseases.
AridolTM: addresses a new market - providing a clinical management tool for asthma and COPD. It is scheduled to complete Phase III clinical trials in Q3 of 2004, with the initial product launch scheduled for Q3 of 2005.
BronchitolTM: a new therapeutic targeting cystic fibrosis, bronchiectasis, and chronic bronchitis. It is scheduled to complete Phase II clinical trials in H2 of 2004, with Phase III clinical trials scheduled to commence in H1 of 2005. The initial product launch is scheduled for CY 2008
PXS25: inhibits immune cell trafficking and is being developed for the treatment of multiple sclerosis and other autoimmune diseases.
PXS2000: represents a new class of anti-inflammatory agent under development for rheumatoid arthritis.
Pharmaxis is building a fully integrated specialist pharmaceutical company with activities spanning research and development through to manufacture, marketing, and distribution.
The company's board of directors and senior management team has extensive experience in developing and commercializing successful breakthrough products.
Last Updated: 05-20-04